Spyre Therapeutics reports positive topline Phase 2 colitis data

 

Spyre Therapeutics reports positive topline Phase 2 SKYLINE Part A results for SPY001 in moderate-to-severe ulcerative colitis, meeting primary histopathology endpoint

• Trial showed strong rates of clinical remission and endoscopic improvement in patients with moderate-to-severe ulcerative colitis.
• Enrollment is transitioning into Part B cohorts of the Phase 2 SKYLINE trial following Part A induction results.

https://finviz.com/quote.ashx?t=SYRE&p=d